MX2013005050A - Derivados de indol. - Google Patents

Derivados de indol.

Info

Publication number
MX2013005050A
MX2013005050A MX2013005050A MX2013005050A MX2013005050A MX 2013005050 A MX2013005050 A MX 2013005050A MX 2013005050 A MX2013005050 A MX 2013005050A MX 2013005050 A MX2013005050 A MX 2013005050A MX 2013005050 A MX2013005050 A MX 2013005050A
Authority
MX
Mexico
Prior art keywords
indole derivatives
bradykinin
racemates
painful
therapy
Prior art date
Application number
MX2013005050A
Other languages
English (en)
Inventor
Istvan Vago
Istvan Borza
Sandor Farkas
Monika Vastag
Gyula Beke
Katalin Hornok
Gyula Attila Benyei
Eva Bozo
Andrea Papp
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of MX2013005050A publication Critical patent/MX2013005050A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La presente invención se relaciona con los derivados de indol de la fórmula (I), donde R1-R6 y X se definen en las reivindicaciones, con los antípodos ópticos o los racematos y/o las sales de los mismos que son antagonistas selectivos de la bradiquinina B1, con el proceso para producir estos compuestos, con las composiciones farmacológicas que los contienen y con su uso en la terapia o en la prevención de las condiciones dolorosas e inflamatorias.
MX2013005050A 2010-11-05 2011-11-04 Derivados de indol. MX2013005050A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU1000598A HUP1000598A2 (en) 2010-11-05 2010-11-05 Indole derivatives
PCT/HU2011/000104 WO2012059776A1 (en) 2010-11-05 2011-11-04 Indole derivatives

Publications (1)

Publication Number Publication Date
MX2013005050A true MX2013005050A (es) 2013-12-06

Family

ID=89990047

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005050A MX2013005050A (es) 2010-11-05 2011-11-04 Derivados de indol.

Country Status (17)

Country Link
US (1) US20130217702A1 (es)
EP (1) EP2635567B1 (es)
JP (1) JP2013542951A (es)
KR (1) KR20130130733A (es)
CN (1) CN103201276B (es)
AP (1) AP2013006867A0 (es)
AU (1) AU2011324958A1 (es)
BR (1) BR112013011192A2 (es)
CA (1) CA2812655A1 (es)
CU (1) CU24136B1 (es)
EA (1) EA022939B1 (es)
HU (2) HUP1000598A2 (es)
IL (1) IL225393A0 (es)
MX (1) MX2013005050A (es)
NZ (1) NZ610699A (es)
SG (1) SG189833A1 (es)
WO (1) WO2012059776A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190156B1 (ar) * 2016-12-23 2023-09-17 Bayer Pharma AG أميدات عطرية لحمض الكربوكسيليك بصفتها مضادات لمستقبلة البراديكينين b1
US20210317092A1 (en) 2016-12-23 2021-10-14 Bayer Pharma Aktiengesellschaft Tetrazole containing compounds
CN112573978B (zh) * 2019-09-30 2022-05-13 北京大学 一种芳基卤化物的高效卤化合成方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227841A (en) 1988-02-12 1991-08-27 Merck Sharp & Dohme Heterocyclic compounds with at least two non-condensed five membered rings and pharmaceutical compositions
GB9716656D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
FR2822827B1 (fr) 2001-03-28 2003-05-16 Sanofi Synthelabo Nouveaux derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant
WO2002099388A2 (en) 2001-06-07 2002-12-12 Merck & Co., Inc. Benzodiazepine bradykinin antagonists
WO2003000657A1 (fr) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Derives de diamine
AR038377A1 (es) * 2002-02-08 2005-01-12 Merck & Co Inc Derivados de n-bifenil-aminocicloalcancarboxamida (con sustitucion con metilo)
IL166426A0 (en) * 2002-08-29 2006-01-15 Merck & Co Inc N-biarylmethyl aminocycloalkanecarboxamide derivatives
US6908921B2 (en) 2002-12-13 2005-06-21 Merck & Co., Inc. Quinoxalinone derivatives as bradykinin B1 antagonists
US7393873B2 (en) 2003-07-02 2008-07-01 Merck & Co., Inc. Arylsulfonamide derivatives
CN1832922A (zh) * 2003-08-07 2006-09-13 默克公司 磺酰基取代的n－(联芳基甲基)氨基环丙烷甲酰胺类
CA2534188A1 (en) * 2003-08-07 2005-02-24 Merck & Co., Inc. Sulfonyl substituted n-(biarylmethyl) aminocyclopropanecarboxamides
CN1926136A (zh) * 2004-03-02 2007-03-07 默克公司 作为缓激肽拮抗剂的氨基环丙烷羧酰胺衍生物
US7517899B2 (en) 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
ES2515101T3 (es) 2004-06-04 2014-10-29 Debiopharm International Sa Derivados de acrilamida como agentes antibióticos
US20100286211A1 (en) 2004-10-08 2010-11-11 Biswajit Das Oxazolidinone derivatives as antimicrobials
EP1912976B1 (en) 2005-07-21 2008-11-12 F. Hoffmann-Roche AG Indol-3-yl-carbonyl-piperidin-benzoimidazole derivatives as v1a receptor antagonists
FR2894964B1 (fr) * 2005-12-19 2008-02-22 Cerep Sa Composes a base de quatre cycles aromatiques, preparation et utilisations
WO2007101007A2 (en) 2006-02-23 2007-09-07 Neurogen Corporation Aryl sulfonyl heterocycles
DE102007034620A1 (de) 2007-07-25 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue B1-Antagonisten
AR068509A1 (es) 2007-09-19 2009-11-18 Jerini Ag Antagosnistas del receptor de bradiquinina b1
PE20091782A1 (es) 2008-04-08 2009-11-15 Gruenenthal Chemie Derivados de sulfonamida sustituida
US20090270394A1 (en) * 2008-04-28 2009-10-29 Galemmo Jr Robert Cyclylamine derivatives as calcium channel blockers
PE20120360A1 (es) * 2009-02-26 2012-04-14 Boehringer Ingelheim Int Compuestos en calidad de antagonistas de bradiquinina b1

Also Published As

Publication number Publication date
HU1000598D0 (en) 2010-12-28
CA2812655A1 (en) 2012-05-10
SG189833A1 (en) 2013-06-28
EA201300541A1 (ru) 2013-08-30
EP2635567B1 (en) 2015-10-28
HUP1000598A2 (en) 2012-09-28
EA022939B1 (ru) 2016-03-31
CU24136B1 (es) 2015-11-27
IL225393A0 (en) 2013-06-27
WO2012059776A1 (en) 2012-05-10
NZ610699A (en) 2015-08-28
BR112013011192A2 (pt) 2016-08-02
EP2635567A1 (en) 2013-09-11
CN103201276B (zh) 2015-02-25
AU2011324958A1 (en) 2013-06-06
CU20130065A7 (es) 2013-07-31
CN103201276A (zh) 2013-07-10
AP2013006867A0 (en) 2013-05-31
KR20130130733A (ko) 2013-12-02
HUE026652T2 (en) 2016-07-28
JP2013542951A (ja) 2013-11-28
US20130217702A1 (en) 2013-08-22

Similar Documents

Publication Publication Date Title
EA201590879A1 (ru) Арилконденсированные и гетероарилконденсированные лактамы
MY162535A (en) Inhibitors of arginase and their therapeutic applications
UA108926C2 (ru) LibreOffice? [2,3-D] +" +" !+
MX361759B (es) Compuestos macrocíclicos de dihidropiridona como inhibidores del factor xia y el uso de los mismos en el tratamiento de un trastorno tromboembólico.
MX345763B (es) Nuevos macrociclos como inhibidores del factor xia.
MX2013006083A (es) Derivados de 6-amino-2-fenilamino-1h-bencimidazola-5-carboxamida y sus uso como inhibidores de prostaglandina e2 sintasa-1 microsomal.
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
MX336381B (es) Boronatos como inhibidores de arginasa.
MY196427A (en) Piperidinyl Indole Derivatives And Their Use As Complement Factor B Inhibitors
MX356010B (es) Compuestos 2-anilino-benzimidazol-6carboxamidas como agentes anti-inflamatorios inhibidores de la prostaglandina e2 sintasa-1 microsómica (mpges-1).
MX2012008874A (es) Macrociclos como inhibidores del factor de coagulacion (fxia).
MX361370B (es) Dihidropiridona p1 como inhibidores del factor xia.
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
MX345780B (es) Inhibidores triciclicos de girasa.
MX2014011354A (es) Compuestos de piridopirimidina sustituida y su uso como inhibidores de tirosina cinasa 3 similar a fms.
MX348451B (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparación y su uso como antagonistas p2y12.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
MX2013004759A (es) Compuestos de oxima como agentes de elevacion de colesterol de lipoproteina de alta densidad (hdl).
MX2013005819A (es) Benzoxazepinas como inhibidores de 3-cinasa/objetivo mamífero de rapamicina (pi3k/mtor) metodos de uso y fabricacion.
MD20160111A2 (ro) Derivaţi diheterociclici legaţi de cicloalchil

Legal Events

Date Code Title Description
FG Grant or registration